ESSA Net Income From Continuing Ops from 2010 to 2024

EPIX Stock  USD 1.79  0.02  1.10%   
ESSA Pharma Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -25.1 M in 2024. During the period from 2010 to 2024, ESSA Pharma Net Loss regression line of annual values had r-squared of  0.75 and arithmetic mean of (14,814,704). View All Fundamentals
 
Net Loss  
First Reported
2013-09-30
Previous Quarter
-9 M
Current Value
-7.2 M
Quarterly Volatility
7.4 M
 
Yuan Drop
 
Covid
Check ESSA Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ESSA Pharma's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 5.9 K or Selling General Administrative of 7.5 M, as well as many indicators such as Price To Sales Ratio of 272.8 K, Dividend Yield of 0.0 or PTB Ratio of 52.01. ESSA financial statements analysis is a perfect complement when working with ESSA Pharma Valuation or Volatility modules.
  
Check out the analysis of ESSA Pharma Correlation against competitors.
For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.

Latest ESSA Pharma's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of ESSA Pharma over the last few years. It is ESSA Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ESSA Pharma's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

ESSA Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(14,814,704)
Geometric Mean0.00
Coefficient Of Variation(86.33)
Mean Deviation10,945,683
Median(11,629,440)
Standard Deviation12,789,442
Sample Variance163.6T
Range36.8M
R-Value(0.87)
Mean Square Error43.9T
R-Squared0.75
Significance0.000029
Slope(2,478,262)
Total Sum of Squares2290T

ESSA Net Income From Continuing Ops History

2024-25.1 M
2023-23.9 M
2022-26.6 M
2021-35.1 M
2020-36.8 M
2019-23.4 M
2018-10.4 M

About ESSA Pharma Financial Statements

ESSA Pharma investors use historical fundamental indicators, such as ESSA Pharma's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in ESSA Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-23.9 M-25.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for ESSA Stock Analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.